Quidel Corporation

Abbott Laboratories' Diagnostics business is increasingly relying on its Cancer Diagnostics arm as respiratory testing volumes remain weak. In the second quarter of 2026, Rapid and Molecular Diagnostics sales fell 8% on a comparable basis due to a weaker-than-normal respiratory season, while Cancer Diagnostics sales grew 13%, driven by mid-teens growth in Cologuard. Peer QuidelOrtho reported respiratory products accounted for 9% of total revenues in the first half of 2026, down from 13% a year earlier, and Danaher's Diagnostics segment core revenues declined 4% in the first quarter of 2026. Abbott shares have fallen 11.6% over the past year, and the stock trades at a forward 12-month price-to-sales ratio of 3.81 times versus the industry median of 2.81 times.

QuidelOrtho Corporation sharply lowered its 2026 outlook after second-quarter results as China purchasing weakened and management adopted more conservative respiratory-season assumptions. The company now expects 2026 revenues of $2.52-$2.60 billion, down from its prior $2.70-$2.75 billion range, while adjusted EBITDA guidance fell to $540-$560 million from $615-$630 million and adjusted earnings expectations dropped to 65-90 cents per share from $1.80-$2.00. Management cited the second draft of China's in-vitro diagnostics pricing guidelines, which broadened product coverage and expanded the pilot from three provinces to six, leading customers to reduce inventories more quickly than anticipated. QuidelOrtho also shifted away from using an average respiratory season as its planning baseline, now assuming the second-half respiratory environment will be closer to the lower end of historical seasons. Second-quarter Labs revenues rose 3.6% year over year, Immunohematology increased 1.4% and Point of Care advanced 16.3% on a reported basis, but operating activities used $143.6 million of cash during the first six months of 2026 and total debt increased to $2.89 billion at quarter-end from $2.69 billion at the end of the first quarter.

QuidelOrtho Corporation's core diagnostics businesses outside China grew 6% at constant currency in the second quarter, but worsening China visibility and financial pressure keep the investment case constrained. China revenues fell 18.7% on a reported basis and 23.3% at constant currency, with slower distributor purchases ahead of evolving national in-vitro diagnostics pricing guidelines and faster-than-expected inventory reductions. Adjusted EBITDA rose 21% year over year to $129 million, while adjusted gross margin contracted 130 basis points to 44.4%. The company ended the quarter with $123.4 million in cash against $2.89 billion of total debt, and operating activities used $143.6 million of cash in the first six months of 2026. QuidelOrtho is shifting its molecular strategy toward NULEXA following the April acquisition of LEX Diagnostics, but adoption is not assured against rivals like Abbott Laboratories and Danaher Corporation. The stock carries a Zacks Rank #5 (Strong Sell), with a Value Score of B but Growth and Momentum Scores of F.

Simply Wall St has reduced its fair value estimate for QuidelOrtho from $20.50 to $12.00 per share, reflecting lower growth expectations. The revision follows a cut in the revenue growth assumption from 3.76% to 0.81% and a lower assumed future P/E multiple from 5.66x to 3.60x, while the net profit margin assumption was raised slightly to 12.13% and the discount rate increased to 12.54%. Analyst price targets now cluster between $12 and $18, with Citi lifting its target to $18 from $13 while keeping a Neutral rating, and JPMorgan setting a $12 target with an Underweight rating. The divergence highlights ongoing uncertainty about QuidelOrtho's growth path and execution risks.

QuidelOrtho Corporation reported second-quarter 2026 adjusted earnings of 13 cents per share, beating the Zacks Consensus Estimate by 425%, while revenue of $630.9 million surpassed estimates by 2.65%. However, the company lowered its full-year 2026 revenue guidance to $2.52-$2.60 billion from $2.70-$2.75 billion, citing persistent weakness in China and a softer respiratory testing outlook. Adjusted EBITDA guidance was cut to $540-$560 million from $615-$630 million, and adjusted earnings per share guidance was reduced to 65-90 cents from $1.80-$2.00. Shares fell around 25% in Friday's trading session following the reduced outlook.

QuidelOrtho shares have fallen 40.6% over the past six months to $16.68, driven by softer quarterly results. The company's constant currency revenue declined at an average annual rate of 3.4% over the last two years, signaling potential competitive pressures or market saturation. Its free cash flow margin fell by 23 percentage points over five years to negative 6% on a trailing 12-month basis, while return on invested capital has also decreased significantly. The stock now trades at 8.7 times forward earnings, but analysts caution that shaky fundamentals could pose further downside risk.

QuidelOrtho Corporation was removed from several Russell growth-focused benchmarks in late June 2026, including the Russell 3000 Growth, 2000 Growth, 2500 Growth, 3000E Growth, and Small Cap Comp Growth indexes. The company also appointed former Masimo finance chief Micah Young as its new Chief Financial Officer and principal financial officer, effective July 6, 2026. The index exclusions may add short-term share price and liquidity volatility, while Young's experience in finance and capital allocation at other medical technology companies could influence how aggressively QuidelOrtho pursues cost savings and balance sheet resilience. QuidelOrtho recently reported net losses and lowered its 2026 revenue guidance to between US$2.7 billion and US$2.75 billion.